Core First Bank & Trust Gilead Sciences, Inc. Transaction History

Core First Bank & Trust

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$71.58 - $87.29 $7,158 - $8,729	-100 Reduced 5.92%	1,590 $116,000
Q4 2023 Mar 18, 2024	SELL	$73.27 - $83.09 $16,852 - $19,110	-230 Reduced 11.98%	1,690 $136,000
Q4 2022 Feb 15, 2023	SELL	$62.32 - $89.47 $4,487 - $6,441	-72 Reduced 3.61%	1,920 $164,000
Q2 2022 Aug 16, 2022	SELL	$57.72 - $65.01 $50,620 - $57,013	-877 Reduced 30.57%	1,992 $123,000
Q1 2022 May 16, 2022	SELL	$57.92 - $72.58 $19,113 - $23,951	-330 Reduced 10.32%	2,869 $171,000
Q4 2020 Feb 16, 2021	BUY	$56.65 - $64.55 $181,223 - $206,495	3,199 New	3,199 $186,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Core First Bank & Trust, based on Form 13F filings with the SEC.

Stay updated on Core First Bank & Trust with notifications on news.